JP2008543876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543876A5 JP2008543876A5 JP2008517201A JP2008517201A JP2008543876A5 JP 2008543876 A5 JP2008543876 A5 JP 2008543876A5 JP 2008517201 A JP2008517201 A JP 2008517201A JP 2008517201 A JP2008517201 A JP 2008517201A JP 2008543876 A5 JP2008543876 A5 JP 2008543876A5
- Authority
- JP
- Japan
- Prior art keywords
- vasoconstrictor
- skin
- formulation
- epinephrine
- delivery vehicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 21
- 229960005139 epinephrine Drugs 0.000 claims description 21
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 20
- 229960002748 norepinephrine Drugs 0.000 claims description 20
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 20
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 16
- 229960001802 phenylephrine Drugs 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 6
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims description 6
- 229960005192 methoxamine Drugs 0.000 claims description 6
- 229960001360 zolmitriptan Drugs 0.000 claims description 4
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 206010036774 Proctitis Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 229960005016 naphazoline Drugs 0.000 claims description 3
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002133 almotriptan Drugs 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 229960000425 rizatriptan Drugs 0.000 claims description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims 2
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229960002284 frovatriptan Drugs 0.000 claims 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000337 tetryzoline Drugs 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 45
- 239000000203 mixture Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 34
- 238000009472 formulation Methods 0.000 description 33
- 230000000699 topical effect Effects 0.000 description 28
- 230000002087 whitening effect Effects 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 13
- 230000005855 radiation Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- 210000002200 mouth mucosa Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- WNPNNLQNNJQYFA-YIDNRZKSSA-N 4-[(1r)-2-amino-1-hydroxyethyl]benzene-1,2-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.NC[C@H](O)C1=CC=C(O)C(O)=C1 WNPNNLQNNJQYFA-YIDNRZKSSA-N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 6
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000003265 stomatitis Diseases 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 206010028116 Mucosal inflammation Diseases 0.000 description 5
- 201000010927 Mucositis Diseases 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 4
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000674 adrenergic antagonist Substances 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000006934 radiodermatitis Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- WNPNNLQNNJQYFA-UHFFFAOYSA-N [2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]azanium;2,3,4-trihydroxy-4-oxobutanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.NCC(O)C1=CC=C(O)C(O)=C1 WNPNNLQNNJQYFA-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229960004607 alfuzosin Drugs 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- -1 tetrahydrozaline Chemical compound 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69157105P | 2005-06-17 | 2005-06-17 | |
| US60/691,571 | 2005-06-17 | ||
| PCT/US2006/023708 WO2006138691A1 (en) | 2005-06-17 | 2006-06-19 | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015039086A Division JP6348437B2 (ja) | 2005-06-17 | 2015-02-27 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008543876A JP2008543876A (ja) | 2008-12-04 |
| JP2008543876A5 true JP2008543876A5 (enExample) | 2015-04-16 |
| JP5756250B2 JP5756250B2 (ja) | 2015-07-29 |
Family
ID=37570784
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517201A Active JP5756250B2 (ja) | 2005-06-17 | 2006-06-19 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
| JP2015039086A Active JP6348437B2 (ja) | 2005-06-17 | 2015-02-27 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
| JP2016116373A Active JP6473103B2 (ja) | 2005-06-17 | 2016-06-10 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
| JP2018190933A Withdrawn JP2018203788A (ja) | 2005-06-17 | 2018-10-09 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015039086A Active JP6348437B2 (ja) | 2005-06-17 | 2015-02-27 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
| JP2016116373A Active JP6473103B2 (ja) | 2005-06-17 | 2016-06-10 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
| JP2018190933A Withdrawn JP2018203788A (ja) | 2005-06-17 | 2018-10-09 | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8114914B2 (enExample) |
| EP (2) | EP1890732B1 (enExample) |
| JP (4) | JP5756250B2 (enExample) |
| CN (3) | CN107496925A (enExample) |
| AU (1) | AU2006261358B2 (enExample) |
| CA (1) | CA2611496C (enExample) |
| DK (2) | DK1890732T3 (enExample) |
| ES (2) | ES2675228T3 (enExample) |
| HK (1) | HK1245143A1 (enExample) |
| HU (2) | HUE038177T2 (enExample) |
| IL (2) | IL191869A (enExample) |
| PL (2) | PL2656860T3 (enExample) |
| PT (2) | PT2656860T (enExample) |
| TR (1) | TR201809015T4 (enExample) |
| WO (1) | WO2006138691A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| AU2006261358B2 (en) | 2005-06-17 | 2012-05-31 | Wisconsin Alumni Research Foundation | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
| EP1937219B1 (en) | 2005-09-14 | 2015-11-11 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| US8785396B2 (en) * | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN109568740B (zh) | 2008-06-13 | 2022-05-27 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
| MX336361B (es) | 2008-06-20 | 2015-12-03 | Mannkind Corp | Un metodo y un aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion. |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| EP2165706A1 (en) * | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| TWI547487B (zh) | 2009-06-12 | 2016-09-01 | 曼凱公司 | 具限定比表面積之二酮基哌微粒子 |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| SG10201606220QA (en) | 2011-04-01 | 2016-09-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
| US20140343159A1 (en) * | 2011-06-02 | 2014-11-20 | Procertus Biopharm, Inc. | Formulation of small adrenergic agonist salt forms in organic solvents |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| MX2014004983A (es) | 2011-10-24 | 2014-09-22 | Mannkid Corp | Metodos y composiciones para tratar dolor. |
| SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| CN105517607A (zh) | 2013-08-05 | 2016-04-20 | 曼金德公司 | 吹入设备和方法 |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| BR112017009980A2 (pt) * | 2014-11-14 | 2018-02-14 | Follea Int | ?sistema e método para prevenção de alopecia?. |
| ES2904543T3 (es) | 2015-06-11 | 2022-04-05 | ReJoy | Tratamiento de la disfunción sexual |
| WO2019014518A1 (en) * | 2017-07-14 | 2019-01-17 | Galderma Research And Development | METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS |
| JP2020530494A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
| EP3887351A4 (en) * | 2018-11-27 | 2022-11-02 | The Trustees of Columbia University in the City of New York | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FERROPTOSE AND TREATING EXCITOTOXIC DISORDERS |
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
| WO2021084541A1 (en) * | 2019-10-31 | 2021-05-06 | Sol-Gel Technologies Ltd. | Treatment of hair loss disorders with a topical egfr inhibitor |
| WO2023130086A1 (en) * | 2021-12-31 | 2023-07-06 | Jss Research, Llc | Compositions and methods for topical treatment of vascular conditions |
| AU2022443966A1 (en) | 2022-03-04 | 2024-08-22 | Vasodynamics Limited | Topical compositions and methods. |
| CN119313747B (zh) * | 2024-12-17 | 2025-04-15 | 中国海洋大学三亚海洋研究院 | 一种鱼类表皮体色量化方法和装置 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2414918A (en) * | 1941-09-23 | 1947-01-28 | Abramson Harold Alexander | Solutions for the improved nebulization therapy of the lungs and bronchioles |
| US2774789A (en) * | 1947-10-24 | 1956-12-18 | Sterling Drug Inc | 1-arterenol and its acid-addition salts and preparation thereof |
| US2919230A (en) * | 1953-10-29 | 1959-12-29 | Rohm & Haas | Hydrophilic base therapeutic compositions comprising cation-exchange resin |
| BE555319A (enExample) * | 1956-03-21 | 1900-01-01 | ||
| US3039922A (en) * | 1959-08-17 | 1962-06-19 | Carter Prod Inc | Method of administering tablets having decongestant and anti-histaminic activity |
| US3134720A (en) * | 1962-06-27 | 1964-05-26 | Bristol Myers Co | Medicated gels |
| US3574859A (en) * | 1968-07-05 | 1971-04-13 | Carl M Kosti | Process for the treatment of hypertrophied gums |
| GB2122892B (en) * | 1982-07-02 | 1986-01-29 | Squibb & Sons Inc | Nystantin pastille formulation |
| SE457055B (sv) | 1986-08-18 | 1988-11-28 | Ferring Ab | Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser |
| US4853216A (en) * | 1987-04-02 | 1989-08-01 | Bristol-Myers Company | Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects |
| US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| US5013716A (en) | 1988-10-28 | 1991-05-07 | Warner-Lambert Company | Unpleasant taste masking compositions and methods for preparing same |
| US5461042A (en) * | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
| US5374645A (en) * | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
| US5260292A (en) * | 1991-03-05 | 1993-11-09 | Marvin S. Towsend | Topical treatment of acne with aminopenicillins |
| JPH04327533A (ja) | 1991-04-23 | 1992-11-17 | Lion Corp | 抗アレルギー用粘膜局所投与剤 |
| US5534242A (en) | 1994-05-02 | 1996-07-09 | Henry; Richard A. | Lidocaine-vasoconstrictor aerosol preparation |
| US5585398A (en) * | 1994-07-15 | 1996-12-17 | Ernst; Amy A. | Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use |
| NL9401183A (nl) | 1994-07-19 | 1996-03-01 | Nederland Ptt | Modulator/demodulatorinrichting voor koppeling van een dataterminal met een zend/ontvanginrichting, alsmede werkwijzen voor het tot stand brengen van een dataverbinding tussen een eerste en een tweede modulator/demodulatorinrichting. |
| GB9422571D0 (en) | 1994-11-09 | 1995-01-04 | Whitehall Lab Ltd | Haemorrihoidal compositions and method of use |
| CA2154979A1 (en) | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
| US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| EP0946155B2 (en) | 1996-12-23 | 2009-01-21 | S.L.A. Pharma AG | Pharmaceutical composition for treating fecal incontinence |
| GB2370989A (en) | 2001-01-16 | 2002-07-17 | Btg Int Ltd | Piperine analogues for the treatment of skin conditions |
| US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| JP2001131085A (ja) * | 1999-08-25 | 2001-05-15 | Saitama Daiichi Seiyaku Kk | 経皮・経粘膜吸収用の医薬組成物 |
| MXPA02008403A (es) * | 2000-02-28 | 2004-09-27 | Vectura Ltd | Mejoras en o relacionadas con el suministro de farmacos por via oral. |
| US6375982B1 (en) | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
| EP1329217A4 (en) | 2000-10-06 | 2007-04-04 | Takeda Pharmaceutical | Solid preparations |
| GB0028575D0 (en) * | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
| EP1363602A4 (en) | 2001-01-25 | 2006-01-11 | Euro Celtique Sa | LOCAL ANESTHESIA, AND METHOD OF USE |
| EP1997478B1 (en) | 2001-02-15 | 2013-09-04 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| US20040176359A1 (en) | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20020192273A1 (en) | 2001-06-15 | 2002-12-19 | Teri Buseman | Therapeutic patch useful for the treatment of hemorrhoids |
| US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| JP4544391B2 (ja) * | 2001-12-28 | 2010-09-15 | ライオン株式会社 | 眼科用組成物 |
| US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| WO2005014524A2 (en) * | 2003-08-07 | 2005-02-17 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
| JP2007502839A (ja) | 2003-08-21 | 2007-02-15 | トランソラル ファーマシューティカルズ，インコーポレイティド | 口腔粘膜を介して５−ｈｔアゴニストを運搬するための組成物及びその使用方法 |
| US20070219253A1 (en) * | 2003-09-17 | 2007-09-20 | Gul Balwani | Decongestant / antihistaminic / expectorant compositions |
| EP1737434A2 (en) | 2004-04-13 | 2007-01-03 | Alza Corporation | Apparatus and method for transdermal delivery of fentanyl-based agents |
| AU2006261358B2 (en) * | 2005-06-17 | 2012-05-31 | Wisconsin Alumni Research Foundation | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
-
2006
- 2006-06-19 AU AU2006261358A patent/AU2006261358B2/en active Active
- 2006-06-19 WO PCT/US2006/023708 patent/WO2006138691A1/en not_active Ceased
- 2006-06-19 ES ES06773476.4T patent/ES2675228T3/es active Active
- 2006-06-19 CN CN201710850996.9A patent/CN107496925A/zh active Pending
- 2006-06-19 HU HUE06773476A patent/HUE038177T2/hu unknown
- 2006-06-19 CN CN200680021549.2A patent/CN101198362B/zh active Active
- 2006-06-19 PT PT131574857T patent/PT2656860T/pt unknown
- 2006-06-19 US US11/471,047 patent/US8114914B2/en active Active
- 2006-06-19 CA CA2611496A patent/CA2611496C/en active Active
- 2006-06-19 PL PL13157485T patent/PL2656860T3/pl unknown
- 2006-06-19 ES ES13157485T patent/ES2880624T3/es active Active
- 2006-06-19 PL PL06773476T patent/PL1890732T3/pl unknown
- 2006-06-19 EP EP06773476.4A patent/EP1890732B1/en active Active
- 2006-06-19 JP JP2008517201A patent/JP5756250B2/ja active Active
- 2006-06-19 CN CN201410134371.9A patent/CN103948927B/zh active Active
- 2006-06-19 HU HUE13157485A patent/HUE054887T2/hu unknown
- 2006-06-19 PT PT67734764T patent/PT1890732T/pt unknown
- 2006-06-19 DK DK06773476.4T patent/DK1890732T3/en active
- 2006-06-19 TR TR2018/09015T patent/TR201809015T4/tr unknown
- 2006-06-19 EP EP13157485.7A patent/EP2656860B1/en active Active
- 2006-06-19 DK DK13157485.7T patent/DK2656860T3/da active
-
2008
- 2008-06-01 IL IL191869A patent/IL191869A/en active IP Right Grant
-
2011
- 2011-05-12 US US13/106,293 patent/US8247457B2/en active Active
-
2012
- 2012-07-17 US US13/550,662 patent/US20120316246A1/en not_active Abandoned
-
2014
- 2014-06-01 IL IL232904A patent/IL232904A/en active IP Right Grant
-
2015
- 2015-02-27 JP JP2015039086A patent/JP6348437B2/ja active Active
- 2015-11-06 US US14/934,275 patent/US11197836B2/en not_active Expired - Fee Related
-
2016
- 2016-06-10 JP JP2016116373A patent/JP6473103B2/ja active Active
-
2018
- 2018-04-13 HK HK18104863.6A patent/HK1245143A1/zh unknown
- 2018-10-09 JP JP2018190933A patent/JP2018203788A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543876A5 (enExample) | ||
| JP6473103B2 (ja) | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 | |
| JP5144277B2 (ja) | 局所用生体付着性製剤 | |
| CN1293869C (zh) | 用于将锌递送到鼻粘膜的方法和组合物 | |
| JP5731446B2 (ja) | 局所用生体付着性製剤 | |
| JP5276982B2 (ja) | オキシトシンの投与による頭痛の処置のための方法 | |
| WO2007123193A1 (ja) | スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム | |
| US6790980B1 (en) | Tannate compositions and methods of treatment | |
| JP2011515485A (ja) | ロフェキシジンを経粘膜送達するための組成物およびその方法 | |
| CZ20012492A3 (cs) | Prostředek se zlepąenou stabilitou a způsob jeho výroby | |
| TW202239430A (zh) | 外用劑組合物 | |
| JP2022515569A (ja) | フェノルドパムの安定な局所用組成物 | |
| CN119212680A (zh) | 局部组合物和方法 | |
| JP2017066126A (ja) | 口腔粘膜投与用の唾液分泌促進用医薬組成物 | |
| HK1200087B (en) | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |